Calculation of absorbed dose due to the 90Y-DOTATOC peptide receptor radionuclide therapy by MCNP5/X

Strong beta emitters, like 90Y, 177Lu labelled peptide, are used for treatment of neuroendocrine tumours where there is a good expression of somatostatin receptors. In this work, MCNP5/X computer software and ORNL human phantoms were used to calculate absorbed dose due to 90Y labelled DOTATOC in the...

Full description

Saved in:
Bibliographic Details
Published inNuclear technology & radiation protection Vol. 33; no. 4; pp. 380 - 385
Main Authors Jeremic, Marija, Matovic, Milovan, Pantovic, Suzana, Nikezic, Dragoslav, Krstic, Dragana
Format Journal Article
LanguageEnglish
Published Belgrade Vinca Institute of Nuclear Sciences 2018
VINCA Institute of Nuclear Sciences
Subjects
90Y-DOTATOC
Beta rays
Bremsstrahlung
Dosage
dosimetry
Emitters
Lungs
Mathematical analysis
Monte Carlo simulations
Organs
Pancreas
peptide receptor radionuclide therapy
Peptides
Radiation therapy
Radioisotopes
Receptors
Tumors
Yttrium isotopes
Online AccessGet full text

Cover

More Information
Summary:Strong beta emitters, like 90Y, 177Lu labelled peptide, are used for treatment of neuroendocrine tumours where there is a good expression of somatostatin receptors. In this work, MCNP5/X computer software and ORNL human phantoms were used to calculate absorbed dose due to 90Y labelled DOTATOC in the peptide receptor radionuclide therapy. Tumour was considered as a sources of beta radiation and represented as a sphere with diameter of 1-4 cm and 5 cm in liver, pancreas, and lungs. Results are expressed as absorbed dose per unit of cumulated activity, S ? value in units mGy?(MBq?s)?1. The far largest dose is in tumour itself, then in organ which contains the tumour. Doses in other organs, where the metastasis are the most frequent, due to the bremsstrahlung radiation, are much smaller and could be neglected. The largest dose, 8.66?10?3 mGy?(MBq?s)?1 was obtained for tumour with size of 3 cm.
ISSN:1451-3994
1452-8185
DOI:10.2298/NTRP180411006J